Finance

Lists
Why is DNA down 2.84%?
Dive Deeper
DNA:NYSE
Ginkgo Bioworks Holdings Inc
$8.20
-2.84%
(-0.24) 1D
$8.10
-1.22% (-0.100)
Pre-market
Closed: Nov 19, 4:00:04 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DNA...
Open
$8.61
High
$8.99
Low
$8.09
Mkt. cap
506.97M
Avg. vol.
2.59M
Volume
1.12K
52-wk high
$18.22
52-wk low
$5.37
EPS
-$4.19
Beta
1.74
Shares outstanding
53.94M
No. of employees
485
Open
$8.61
High
$8.99
Low
$8.09
Mkt. cap
506.97M
Avg. vol.
2.59M
Volume
1.12K
52-wk high
$18.22
52-wk low
$5.37
EPS
-$4.19
Beta
1.74
Shares outstanding
53.94M
No. of employees
485
News stories
From web sources and news partners
Profile
Ginkgo Bioworks Holdings, Inc. is an American biotechnology company founded in 2008 by five scientists from MIT. The company uses genetic engineering to produce bacteria with industrial applications for other biotech companies, reducing the need for other companies to repeat the initial stages of synthetic biology design. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange through a SPAC merger on September 17, 2021. Wikipedia
About Ginkgo Bioworks Holdings Inc
CEOJason Kelly
Employees485
Founded2008
HeadquartersBoston, Massachusetts, United States
SectorHealth Care
Industry-
Websiteginkgo.bio
Analyst ratings
Based on 2 analysts giving stock ratings to DNA in the past 3 months
Sell
Buy
0
Hold
1
Sell
1
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for DNA in the last 3 months.
Highest
Current $8.20
$11.00 (+34.15%)
Average
$8.00 (-2.44%)
Lowest
$5.00 (-39.02%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brendan Smith
TD Cowen
Hold
Maintained
$11.00
+34.1%
10/13/2026
Mark Massaro
BTIG
Sell
Reiterated
$5.00
-39%
09/04/2026
Jared Haase
William Blair
Sell
Maintained
-
-
08/13/2026
Matt Larew
William Blair
Sell
Reiterated
-
-
05/11/2026
Last report
Nov 5, 2026
Fiscal period
Q3 2026
-$0.48 / -$0.54
+10.35%beat
Revenue / Est. (USD)
27.71M / 21.51M
+28.83%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
33.40M
19.47M
20.16M
27.71M
Cost of goods sold
7.30M
3.10M
1.72M
1.81M
Cost of revenue
7.30M
3.10M
1.72M
1.81M
Research and development expenses
50.13M
49.92M
46.21M
40.94M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
46.01M
37.83M
29.67M
28.59M
Operating expense
96.14M
87.75M
75.88M
69.54M
Total operating expenses
103.44M
90.85M
77.60M
71.34M
Operating income
-70.05M
-71.37M
-57.44M
-43.63M
Other non operating income
821.00K
-388.00K
809.00K
1.61M
EBT including unusual items
-81.39M
-76.14M
-57.19M
-41.26M
EBT excluding unusual items
-62.01M
-68.17M
-58.07M
-40.97M
Income tax expense
-643.00K
-80.00K
128.00K
-271.00K
Effective tax rate
0.79%
0.10%
-0.22%
0.66%
Other operating expenses
-
-
-
-
Net income
-80.75M
-82.59M
-46.71M
-40.98M
Net profit margin
-241.80%
-424.09%
-231.74%
-147.90%
Earnings per share
-0.77
-
-0.73
-0.48
Interest and investment income
7.21M
3.60M
3.23M
3.06M
Interest expense
-
-
-
-
Net interest expenses
7.21M
3.60M
3.23M
3.06M
Depreciation and amortization charges
-
-
-
-
EBITDA
-61.08M
-62.78M
-49.23M
-35.80M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps